... maker GlaxoSmithKline said Wednesday government regulators rejected a new use of its drug Advair Diskus in patients with a common respiratory disease. ...
AP - August 8, 2007 12:13 PM ET RESEARCH TRIANGLE PARK, NC - Government regulators have rejected a new use of GlaxoSmithKline's Advair Diskus drug in ...
... Sanofi-Aventis' weight-loss drug Zimulti, and even a higher dose of GlaxoSmithKline's Advair Diskus for bronchitis and emphysema symptoms. ...
... Sanofi-Aventis' weight-loss drug Zimulti, and even a higher dose of GlaxoSmithKline's Advair Diskus for bronchitis and emphysema symptoms. ...
GlaxoSmithKline has been left stunned by a decision by US regulators to issue a ‘not approvable’ letter the highest dose of its asthma inhaler Advair Diskus ...
British drug giant Glaxosmithkline's hopes to expand labeling for Advair Diskus, which is used to control asthma and chronic obstructive pulmonary disease, ...
8 (Bloomberg) -- GlaxoSmithKline Plc failed to win US approval of an added use that would have expanded sales of the asthma inhaler Advair Diskus, ...
GlaxoSmithKline PLC said US health regulators declined to approve a higher-strength version of its inhaled Advair Diskus for chronic obstructive pulmonary ...
all 5 news articles
AP - August 8, 2007 12:13 PM ET RESEARCH TRIANGLE PARK, NC - Government regulators have rejected a new use of GlaxoSmithKline's Advair Diskus drug in ...